drugset / Trial / NCT01644110
Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF
NaSingle-groupOpen-labelTreatment
Summary
The proposed study is an open-label, single-arm, Phase-Ib/II trial to assess the efficacy of oral drug combination ruxolitinib and pomalidomide in primary and secondary MF patients.
Timeline
- Start
- 2013-08
- Primary completion
- 2024-04
- Completion
- 2024-04-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pomalidomide | Other / unclassified | 0.5 mg | Oral |
| Subject | Pomalidomide | Other / unclassified | 2 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 25 mg | Oral |